We reflect on an exceptional 2023 and look forward to the promising opportunities that await in 2024. This year marked a significant decision – a refocus on our origins in research and biomarker development. Our collective efforts have propelled us forward, enhancing our offerings and services. The industry’s growing recognition of the value of MRI-based muscle health assessments has been truly rewarding. This acknowledgment extends to their crucial role in drug development and identifying patients at heightened risk for complications.
Entering the new year, our team is energized and enthusiastic to advance our groundbreaking work in close collaboration with our customers in clinical trials and clinical research.
We wish everyone a restful holiday season and a prosperous new year!